Skyrizi's momentum defies J&J's rival Icotyde as AbbVie raises full-year sales guidance

AbbVie's Skyrizi shrugs off new competition as it thrives in growing psoriasis market

Since they were approved four months apart in 2019, AbbVie’s Skyrizi and Rinvoq have been joined at the hip, central to the Illinois drugmaker's hopes that the duo could replace aging immunology su | Seven years after…